Cardiosense
Cardiosense, Inc.
CardioTag™ is the world's first noninvasive device delivering PCWP at point-of-care, enabling clinicians to precisely manage Heart Failure patients. FDA-cleared Class II.
cardiosense.com · Chicago, IL
Funding event
The round itself, as filedInferred stageSeries B
Sold of offered$26.1M of $42.0M
Filed2026-08-24
Days since filing40
- Exemption claimed
- Rule 506(b)
- First-ever Form D
- No
- Date of first sale
- 2026-08-07
Investors
No investors named: Form D does not list them
Officers on the filing
Names and roles as filed; addresses are never stored- Eric MeizlishExecutive Officer · Director
- Andrew Michael CarekExecutive Officer
- Daniel GottliebDirector
- Bimal ShahDirector
- Jeffrey TrostDirector
- Lauren Pierce FlickingerDirector
- Omer Tolga InanExecutive Officer · Director
Health flags
Three flags, each with the raw inputs behind it · as of 2026-10-03UndersubscribedNot flagged62.2% sold1.9 months since first sale
Prior raiseNot flaggedPrior raise not known—
AmendedNot flaggedNo amendmentNo D/A on file
Open roles
On the employer's own careers page · checked 2026-09-211
Pre-posting windowNot enough dataShown once this sector and stage have 20 observed lags from filing to first posting.
- Head of Technical Operations and Clinical EngineeringSEP 21Chicago, IL · R&D · Remote · open 13 days
Also raised in Health & bio
Same sector, 28 days to 2026-10-04Altay TherapeuticsSeries A · $15.7M of $45.1M · San Carlos, CAQuietCarebilitySeries A · $8.8M of $8.8M · Richardson, TXQuiet
75 rounds in Health & bio in the 28 days to 2026-10-02, against 71 in the 28 days before.